Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hydrocodone is a synthetic opioid analgesic derived from codeine, primarily used for the management of moderate to severe pain and as an antitussive (cough suppressant)[3][4][5]. It acts on the central nervous system by binding to and activating mu-opioid receptors, resulting in analgesia, euphoria, sedation, and suppression of cough reflex[2][3][7]. Hydrocodone is often formulated in combination with other agents such as acetaminophen or ibuprofen. It has a high potential for dependence and abuse. The drug was first approved by the FDA in 1943 as part of the cough suppressant syrup Hycodan[5]. Hydrocodone's more potent metabolite is hydromorphone.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on hydrocodone.